EHMT2 and neoplasm: CM-272 as a first-in-class dual inhibitor of G9a/DNMTs inhibits cell vitality, promotes apoptosis and prolongs the survival of AML and DLBCL mouse model, proving to be a promising drug in tumor therapy [140].